title: Biological effect of human serum collected before and after oral intake of Pygeum africanum on various benign prostate cell cultures.
abstract: Pygeum africanum (Tadenan) is a popular phytotherapeutic agent used in the treatment of symptomatic benign prostatic hyperplasia. The active compounds of the drug have not been identified, and determining the plasma concentration of the drug is, therefore, not possible. Because there are conflicting results on the efficacy of this drug, we aimed to investigate its effect on prostate cell growth in vitro using human serum collected before and after Pygeum africanum intake. We used primary and organotypic cultures of human prostatic stromal myofibroblast cell line WPMY and prostatic epithelial cell line PNT2. We also used fresh benign prostatic tissue. The serum of a treated man induced decreases in the proliferation of primary cells, organotypic cells and WPMY cells but not PNT2 cells. We also analysed the effect of treated serum on the gene expression profile of WPMY cells. The transcriptome analysis revealed an upregulation of genes involved in multiple tumour suppression pathways and a downregulation of genes involved in inflammation and oxidative-stress pathways. The oral intake of Pygeum africanum resulted in serum levels of active substances that were sufficient to inhibit the proliferation of cultured myofibroblasts prostatic cells. This inhibition was associated with changes in the transcriptome.
authors.affiliation: Nuffield Department of Surgical Science, University of Oxford, Oxford, UK. stephanelarre@yahoo.fr
authors.forename: Stéphane
authors.initials: S
authors.lastname: Larré
authors.forename: Philippe
authors.initials: P
authors.lastname: Camparo
authors.forename: Eva
authors.initials: E
authors.lastname: Comperat
authors.forename: Delphine
authors.initials: D
authors.lastname: Boulbés
authors.forename: Mohammed
authors.initials: M
authors.lastname: Haddoum
authors.forename: Sylvain
authors.initials: S
authors.lastname: Baulande
authors.forename: Pascal
authors.initials: P
authors.lastname: Soularue
authors.forename: Pierre
authors.initials: P
authors.lastname: Costa
authors.forename: Olivier
authors.initials: O
authors.lastname: Cussenot
mesh_terms: D000284:Administration, Oral; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D004847:Epithelial Cells / Q000166:cytology; D020869:Gene Expression Profiling; D006801:Humans; D008297:Male; D008875:Middle Aged; D058628:Myofibroblasts / Q000166:cytology; D008517:Phytotherapy; D010936:Plant Extracts / Q000008:administration & dosage*; D011467:Prostate / Q000166:cytology* / Q000378:metabolism; D011470:Prostatic Hyperplasia / Q000097:blood* / Q000188:drug therapy / Q000473:pathology; D000068218:Prunus africana / Q000737:chemistry*; D044967:Serum / Q000502:physiology*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D010936:Plant Extracts